Recurrent pericarditis (RP) is an autoinflammatory disease with negative impacts on patient quality of life. RHAPSODY, a global Phase 3 study, evaluated rilonacept, a once-weekly IL-1α/IL-1β trap, in RP.

RHAPSODY: Rilonacept, an IL-1α and IL-1β Trap, Resolves Pericarditis Episodes and Reduces Risk of Recurrence in a Phase 3 Trial of Patients with Recurrent Pericarditis

The Foundation in Cardiology Practice program will offer a comprehensive review of the fundamentals and most important changes in cardiovascular medicine. Program topics will provide details to ensure patients receive the highest, most up-to-date quality of care and achieve the best possible outcomes when returning to your practice.   Electronic posters offer a great opportunity to connect with a look into the future and learn from colleagues to keep the best interest of the patient in mind when providing care.